News Perspective Therapeutics, Inc.

Stocks

CATX

US46489V3024

Biotechnology & Medical Research

Market Closed - NYSE Other stock markets 04:00:00 2026-08-06 pm EDT			5-day change	1st Jan Change
2.970 ^USD	+1.02%		-0.67%	+8.00%

Jul. 28	Perspective Therapeutics' Neuroendocrine Tumor Therapy Receives EU Orphan Drug Designation	MT
Jul. 17	Perspective Therapeutics Data On 212Pb VMT-a-NET Accepted For Oral Presentation At ESMO Congress 2026	CI

All News

Mentions Relevance

Jul. 31	Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results	AQ
Jul. 28	Perspective Therapeutics' Neuroendocrine Tumor Therapy Receives EU Orphan Drug Designation	MT
Jul. 28	Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs	AQ
Jul. 17	Perspective Therapeutics Data On 212Pb VMT-a-NET Accepted For Oral Presentation At ESMO Congress 2026	CI
Jul. 17	Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026	AQ
Jul. 08	Perspective Therapeutics, Inc. Announces Executive Changes	CI
Jul. 08	Perspective Therapeutics Names Paul Lyne Chief Science Officer as Co-Founder Michael Schultz Moves to Advisory Role	MT
Jul. 08	Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor	AQ
Jun. 03	Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort	MT
Jun. 03	Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study	AQ
Jun. 03	Perspective Therapeutics Doses First Patient with [212Pb]Vmt-?-Net in Meningioma Cohort of Phase 1/2A Study	CI
May. 21	Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma	AQ
May. 18	Perspective Therapeutics, Inc. Announces First Patients Dosed In New Cohorts Of Ongoing Phase 1/2a Studies	CI
May. 18	Perspective Therapeutics Doses First Patients for New Cohorts of Two Phase 1/2a Studies in Tumors	MT
May. 18	Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies	AQ
May. 13	Perspective Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 02:20 PM
May. 11	Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 11	Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results	AQ
May. 09	Perspective Therapeutics, Inc. - Shareholder/Analyst Call
Apr. 24	Perspective Therapeutics to Provide Several Upcoming Corporate Updates	AQ
Apr. 20	Perspective Therapeutics Provides Updated Interim Results From Phase 1/2a Cancer Trial	MT
Apr. 20	Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting	AQ
Apr. 20	Perspective Therapeutics Inc Presents Updated Interim Data of [212Pb]VMT-a-NET in Ongoing Phase 1/2A Clinical Trial	CI
Apr. 02	Perspective Therapeutics to Participate in Upcoming Investor Conferences	AQ
Mar. 22	Perspective Therapeutics, Inc.(NYSEAM:CATX) added to S&P Biotechnology Select Industry Index	CI